Search details
1.
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
N Engl J Med
; 388(18): 1657-1667, 2023 May 04.
Article
in English
| MEDLINE | ID: mdl-37133585
2.
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
N Engl J Med
; 388(3): 228-239, 2023 01 19.
Article
in English
| MEDLINE | ID: mdl-36652354
3.
A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer.
BMC Cancer
; 23(1): 708, 2023 Jul 28.
Article
in English
| MEDLINE | ID: mdl-37507657
4.
Body weight loss as a prognostic and predictive factor in previously treated patients with metastatic gastric cancer: post hoc analyses of the randomized phase III TAGS trial.
Gastric Cancer
; 26(4): 626-637, 2023 07.
Article
in English
| MEDLINE | ID: mdl-37106214
5.
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS).
Gastric Cancer
; 25(3): 586-597, 2022 05.
Article
in English
| MEDLINE | ID: mdl-34997449
6.
A phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN-inactivating mutations.
Future Oncol
; 18(30): 3377-3387, 2022 Sep.
Article
in English
| MEDLINE | ID: mdl-36039910
7.
Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma.
Cancer
; 127(3): 372-380, 2021 02 01.
Article
in English
| MEDLINE | ID: mdl-33107983
8.
A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors.
Invest New Drugs
; 39(2): 469-476, 2021 04.
Article
in English
| MEDLINE | ID: mdl-32939607
9.
Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer.
Invest New Drugs
; 39(1): 193-201, 2021 02.
Article
in English
| MEDLINE | ID: mdl-32915419
10.
A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations.
Invest New Drugs
; 39(5): 1324-1334, 2021 10.
Article
in English
| MEDLINE | ID: mdl-33774767
11.
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors.
Invest New Drugs
; 39(4): 1089-1098, 2021 08.
Article
in English
| MEDLINE | ID: mdl-33686452
12.
Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study.
Gastric Cancer
; 24(4): 970-977, 2021 07.
Article
in English
| MEDLINE | ID: mdl-33713215
13.
A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer.
Invest New Drugs
; 38(5): 1588-1597, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32246224
14.
A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma.
Invest New Drugs
; 37(1): 118-126, 2019 02.
Article
in English
| MEDLINE | ID: mdl-29995286
15.
Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma.
Liver Int
; 39(8): 1468-1477, 2019 08.
Article
in English
| MEDLINE | ID: mdl-30963691
16.
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.
Br J Cancer
; 119(10): 1208-1214, 2018 11.
Article
in English
| MEDLINE | ID: mdl-30318515
17.
Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid tumors.
Invest New Drugs
; 33(2): 432-9, 2015 Apr.
Article
in English
| MEDLINE | ID: mdl-25640850
18.
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors.
Invest New Drugs
; 33(6): 1206-16, 2015 Dec.
Article
in English
| MEDLINE | ID: mdl-26377590
19.
A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer.
Invest New Drugs
; 33(3): 710-9, 2015 Jun.
Article
in English
| MEDLINE | ID: mdl-25902900
20.
Effect of Futibatinib on Cardiac Repolarization: Results of a Randomized, Controlled, Double-Blind, QT/QTc, Phase 1 Study in Healthy Subjects.
Clin Pharmacol Drug Dev
; 12(3): 304-313, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36404525